Literature DB >> 11141638

Vogt-Koyanagi-Harada disease.

R W Read1, N A Rao, E T Cunningham.   

Abstract

Vogt-Koyanagi-Harada (VKH) disease affects primarily persons who are Asian, Latino, Native American, or Asian Indian. Women appear to be affected more commonly than men, and VKH disease may occur at all ages, including childhood. Experimental data continue to support an autoimmune etiology for VKH disease, directed most probably against an antigenic component of the melanocyte, possibly tyrosinase or a tyrosinase-related protein. The clinical diagnosis of VKH disease continues to be based on physical findings. Newer imaging modalities such as magnetic resonance imaging, indocyanine green angiography, and digital image analysis have not added appreciably to our understanding of the condition. First-line therapy consists of high-dose corticosteroids, with use of corticosteroid-sparing agents for resistant or recalcitrant disease. Complications are the main cause of reversible and irreversible vision loss, with subretinal fibrosis and choroidal neovascular membranes having particularly poor prognoses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11141638     DOI: 10.1097/00055735-200012000-00009

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  24 in total

1.  Repeatability and reproducibility of manual choroidal volume measurements using enhanced depth imaging optical coherence tomography.

Authors:  Jay Chhablani; Giulio Barteselli; Haiyan Wang; Sharif El-Emam; Igor Kozak; Aubrey L Doede; Dirk-Uwe Bartsch; Lingyun Cheng; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-24       Impact factor: 4.799

Review 2.  Understanding the role of aldose reductase in ocular inflammation.

Authors:  U C S Yadav; S K Srivastava; K V Ramana
Journal:  Curr Mol Med       Date:  2010-08       Impact factor: 2.222

3.  Primary diffuse large B-cell lymphoma of the spleen with coincident serous retinal detachments responsive to corticosteroids.

Authors:  Shree K Kurup; Grace Levy-Clarke; Katherine R Calvo; Elaine S Jaffe; Robert B Nussenblatt; Chi-Chao Chan
Journal:  Clin Exp Ophthalmol       Date:  2007-07       Impact factor: 4.207

Review 4.  Gender disparities in ocular inflammatory disorders.

Authors:  Hatice Nida Sen; Janet Davis; Didar Ucar; Austin Fox; Chi Chao Chan; Debra A Goldstein
Journal:  Curr Eye Res       Date:  2014-07-02       Impact factor: 2.424

5.  Choroidal imaging: A review.

Authors:  Jay Chhablani; Ian Y Wong; Igor Kozak
Journal:  Saudi J Ophthalmol       Date:  2014-03-20

6.  The association of systemic disorders with Vogt-Koyanagi-Harada and sympathetic ophthalmia.

Authors:  Ali Al-Halafi; Hassan Al Dhibi; Issam H Hamade; Charbel T Bou Chacra; Khalid F Tabbara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-06-30       Impact factor: 3.117

7.  Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome.

Authors:  Lihteh Wu; Teodoro Evans; Mario Saravia; Ariel Schlaen; Cristobal Couto
Journal:  Jpn J Ophthalmol       Date:  2009-01-30       Impact factor: 2.447

8.  Periocular corticosteroid injections in uveitis: effects and complications.

Authors:  H Nida Sen; Susan Vitale; Sapna S Gangaputra; Robert B Nussenblatt; Teresa L Liesegang; Grace A Levy-Clarke; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; John H Kempen
Journal:  Ophthalmology       Date:  2014-07-11       Impact factor: 12.079

9.  Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease.

Authors:  Sunao Sugita; Hiroshi Takase; Tatsushi Kawaguchi; Chikako Taguchi; Manabu Mochizuki
Journal:  Int Ophthalmol       Date:  2007-01-26       Impact factor: 2.029

10.  The spectrum of Vogt-Koyanagi-Harada disease in Tunisia, North Africa.

Authors:  Moncef Khairallah; Sonia Zaouali; Riadh Messaoud; Sami Chaabane; Sonia Attia; Salim Ben Yahia; Kamel Hmidi
Journal:  Int Ophthalmol       Date:  2007-01-04       Impact factor: 2.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.